Excited By Unique Capabilities Of Zydus Cadila, Eli Lilly Partners For Research In Cardiovascular Drugs
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - After striking collaborative research deals with India's Piramal Life Sciences, Jubilant Organosys and Suven, U.S. drug giant Eli Lilly has added Zydus Cadila as its latest partner for drug discovery and development of new cardiovascular treatments
You may also be interested in...
Asia Spotlight: FDA Eli Lilly Global External R&D VP Robert Armstrong On Attracting Indian Innovators As Partners
On the second Monday of each month, "The Pink Sheet" provides exclusive news and commentary on the Asia biopharma market from the editors of its affiliated online publication, PharmAsia News. Register at http://pharmasianews.elsevierbi.com/PAN_Trial_LP.html for a free trial.
Asia Spotlight: FDA Eli Lilly Global External R&D VP Robert Armstrong On Attracting Indian Innovators As Partners
On the second Monday of each month, "The Pink Sheet" provides exclusive news and commentary on the Asia biopharma market from the editors of its affiliated online publication, PharmAsia News. Register at http://pharmasianews.elsevierbi.com/PAN_Trial_LP.html for a free trial.
Eli Lilly Global External R&D VP Robert Armstrong On Attracting Indian Innovators As Partners: An Interview With PharmAsia News
Robert Armstrong, VP, Global External R&D at Eli Lilly is entrusted with perhaps the most challenging task in his organization - cherry-picking the best research partners to help enrich Lilly's pipeline of future drugs - yet keep costs on those multiple research projects as low as possible. Armstrong, who has struck many deals with Indian firms including a joint venture with Jubilant, advocates openness in communication with his partners, but said in an interview with PharmAsia News' India bureau that overcoming challenges and reaching targeted milestones is the true test for strong partnerships.